← All indications
Blood Loss, Surgical
Loss of blood during a surgical procedure.
Drugs by status
Approved for this indication (1)
Phase 4 trials (33)
- ringer's lactate
- desmopressin
- oxytocin
- human fibrin
- carbetocin
- nifedipine
- ergonovine
- ferric carboxymaltose
- sevoflurane
- albumin (Human)
- warfarin
- iron dextran
- labetalol
- human factor ix complex (prothrombin complex concentrate)
- potassium chloride
- epinephrine
- rocuronium
- levobupivacaine
- bupivacaine
- enoxaparin
- aminocaproic acid
- sodium acetate
- rivaroxaban
- tranexamic acid
- misoprostol
- ethamsylate
- vasopressin
- blood plasma
- thrombin (human coagulation factor iia)
- sodium chloride
- +3 more
Phase 3 trials (11)
Phase 2 trials (7)
Phase 1 trials (3)
Organizations
Organization Involved with Phase 4 Indications (26)
- CSL Behring
- ZymoGenetics
- University of Arizona
- Brown University
- Cedars-Sinai Medical Center
- Harvard University
- Good Samaritan Regional Medical Center, Oregon
- Henry Ford Health System
- Instituto Nacional de Traumatologia e Ortopedia
- Loyola University
- McMaster University
- Thammasat University
- Tufts University
- University of Toronto
- University of Bern
- Mayo Clinic
- University of Copenhagen
- Icahn School of Medicine at Mount Sinai
- Lotus Clinical Research
- Isfahan University
- Erciyes University
- Hospital of Southwest Denmark
- Instituto de Medicina Integral Professor Fernando Figueira
- Vita-Salute University of Milano. Italy
- University of Texas, San Antonio
- The Physicians' Services Incorporated Foundation
Organization Involved with Phase 3 Indications (20)
- Bayer
- Omrix Biopharmaceuticals, Inc.
- Ethicon
- United States Army
- Rockefeller University
- Ain Shams University
- Cairo University
- Gottfried Wilhelm Leibniz Universität Hannover
- Monash University
- The New England Baptist Hospital
- Tel Aviv University
- University of Strasbourg
- University of Queensland
- University of Lille
- Rush University
- RUMC
- University of Barcelona
- Australian Red Cross
- Spanish Clinical Research Network
- Total Definer Research Group
Organization Involved with Phase 2 Indications (9)
Organization Involved with Phase 1 Indications (2)
Organization Involved with Other Experimental Indications (17)
- The Second Clinical Medical College of Jinan University
- Ziekenhuis Oost-Limburg
- Federal University of Minas Gerais
- Kunming Medical University
- Masaryk University
- National Cheng Kung University
- Sichuan University
- University of Chicago
- Jinan University
- Henan Medical University
- University of Sao Paulo
- Basel-Liestal University
- University Hospital Brno
- Shiyan Taihe Hospital
- Guizhou Medical University
- Bezmialem University
- People's Liberation Army of China